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agents had less pronounced effect on the preservation of Safranin O
staining, yet remained better than other tested agents.
Conclusions: PTOA therapies will be most effective if a multi-mecha-
nistic approach is utilized to prevent chondrocyte death andmatrix loss
and to stimulate reparative responses. Combination of treatments that
target three distinct mechanisms: cell membrane protection (P-188),
inhibition of catabolism (anti-TNF-a), and stimulation of anabolic
responses (OP-1) appears to be themost promising approach to biologic
intervention of PTOA. Importantly, this Triad shows promise for rapid
translation into clinical settings since all three factors have already been
approved by the FDA for other use.
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INTRA-ARTICULAR BLOOD COAGULATION AGGRAVATES JOINT
DAMAGE AFTER A BLEED IN A CANINE IN VIVO MODEL
M.E. van Meegeren, G. Roosendaal, A.D. Barten-van Rijbroek,
S.C. Mastbergen, F.P. Lafeber. Univ. Med. Ctr. Utrecht, Utrecht, Netherlands
Purpose: Joint bleeding due to trauma, major joint surgery, or hemo-
philia leads to joint damage. However, it is unclear if there are differ-
ences between coagulating blood and anticoagulated blood with
respect to joint degeneration, especially in vivo. Therefore, we evaluated
in a canine in vivo model whether intra-articular blood exposure is
more destructive in case of coagulating blood compared to anti-
coagulated blood, and whether inﬂammation plays a role in the carti-
lage damaging process.
Methods: In 7 dogs left knees were injected with coagulating blood 4
times a week in week 1 and 4; right knees with saline. In 7 other dogs
anticoagulated, heparinized blood was injected with heparinized saline
as control. Ten weeks after the last injection cartilage matrix turnover
and synovial inﬂammation were analyzed ex vivo. To study cartilage
damage without involvement of synovial inﬂammation, healthy full
thickness human cartilage explants were exposed in vitro to coagulating
and anticoagulated blood for 4 days (n¼6). Cartilage matrix turnover
was determined at day 16.
Results: Canine knees injected with coagulating blood showed an
increase of both newly formed and total (resident) glycosaminoglycans
of 9% and 15%, respectively (p¼0.04 and p¼0.01, respectively), as well as
a decreased proteoglycan content of 6%. Injection with coagulating and
anticoagulated blood caused an increase of proteoglycan synthesis rate
of 24% and 14%, respectively (p¼0.01 and p¼0.04, respectively), as
a characteristic of (ineffective) repair activity. Intra-articular injections
with coagulating blood led to more synovial inﬂammation on macro-
scopy as well as histology (p<0.001and p¼0.01, respectively), in
contrast to knees injected with anticoagulated blood. Coagulation of
blood in vitro resulted in more cartilage damage compared to anti-
coagulated blood. This was expressed as more reduction of proteo-
glycan synthesis rate by coagulating blood compared to anticoagulated
blood (17% difference; p¼0.05), and a higher release of proteoglycans
after exposure to coagulating blood compared to anticoagulated blood
(94% difference; p¼0.01).
Conclusions: This study shows that coagulating blood causes more
long-lasting in vivo joint damage than anticoagulated blood; directly on
cartilage and via inﬂammation. In case of joint surgery prolonged
anticoagulation might limit the harmful effects of intra-articular blood.
Moreover, aspiration of blood would prevent joint damage.
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DEPLETION OF PERLECAN DOMAIN I HEPARAN SULFATE REGULATES
FIBROBLAST GROWTH FACTOR ACTIVITY IN CARTILAGE AND
PROTECTS AGAINST CARTILAGE LOSS AND OSTEOPHYTE
DEVELOPMENT IN POST-TRAUMATIC OSTEOARTHRITIS
C.C. Shu, C.B. Little, J. Melrose. Kolling Inst. of Med. Res., Sydney, Australia
Purpose: Fibroblast growth factors (FGF) -2 and -18 have been sug-
gested as potential therapeutic agents in osteoarthritis (OA). FGF-18
promotes chondrogenesis and cartilage repair in vitro and in animal
models. FGF-2 has demonstrated both chondroprotective and pro-
degradatory properties, potentailly dependent upon variable receptor
expression. Both FGF-2 and -18 signalling require heparan sulfate (HS)
as a coreceptor. Given its pericellular localisation, perlecan (HSPG2) has
been implicated as a critical agent in FGF-2/18 activities. We directly
investigated the role of perlecan domain I HS in the onset and
progression of post-traumatic OA, and whether the effects can be
attributed to altered FGF-2/18 signaling in articular cartilage.Methods:Male 10-weeks old wildtype (WT) and Hspg2 exon-3 null (in
which the domain I HS chains are ablated) mice underwent unilateral
destabilisation of the medial meniscus (DMM). Cartilage damage, sub-
chondral bone sclerosis and osteophyte development were scored 4-
and 8-weeks post-operatively. Femoral head cartilage (3 week old mice
both genotypes) were cultured  IL-1 (10ng/ml)  FGF-2 or -18 (0, 1, 10,
100ng/ml) for 4 days. Sulfated glycosaminoglycan (sGAG) released into
the media was quantiﬁed. Cartilage explant gene expression was ana-
lysed by real time PCR.
Results: There were no differences in cartilage aggrecan loss or struc-
tural damage 4 weeks post-DMM surgery between genotypes. At 8
weeks exon-3 null mice had signiﬁcantly less cartilage erosion thanWT
(Fig 1A). The increase in subchondral bone sclerosis post DMM did not
differ between genotypes, but osteophyte size was signiﬁcantly reduced
in exon-3 null mice at 8 weeks (Fig 1B).
There were no genotypic differences in either basal- or IL-1-stimulated
sGAG release from cartilage explants. FGF-2 did not alter sGAG release
IL-1 in either genotype at any dose. FGF-18 alone did not alter sGAG
release in either genotype, but signiﬁcantly attenuated IL-1-induced
sGAG loss (w35%) only in exon-3 null cartilage.
Therewerenodifferencesbetweengenotype ingeneexpression incontrol
or IL-1 cultures. FGF-2 alonewas generally “pro-catabolic”, up-regulating
Adamts4&5andMmp13mRNA inexon-3null cartilage. In thepresenceof
IL-1, FGF-2 decreased WT RNA yield and Gapdh mRNA, suggestive of the
detrimental effectof FGF-2 in injuredcartilage. FGF-18 in theabsenceof IL-
1 decreasedAdamts4 in both genotypes, andmarkedly suppressedMmp2
expression only in exon-3 null cartilage. Unlike FGF-2, FGF-18 did not
affect cell viability in either genotype in the presence of IL-1.
Figure 1. Cartilage erosion (A) and osteophyte size (B) in surgically
induced OA in WT and Hspg2 exon-3 null mice (n ¼ 17-20/group).
Conclusion: Increased mRNA expression in response to FGF-2
(Adamts4/5, Mmp13) and FGF-18 (Mmp2) in exon-3 null cartilage
conﬁrmed the importance of perlecan domain I HS, suggesting it acts by
sequestration and reduced presentation to receptors in cartilage. The in
vitro data suggests that reduced cartilage erosion in exon-3 null mice
post DMM surgerymay be associatedwith increased FGF-18 rather than
altered FGF-2 signalling in chondrocytes in the absence of perlecan
domain I HS. The mechanism behind reduced osteophyte size in exon-3
null mice is unclear but may result from altered stem cell differentia-
tion, endochondral ossiﬁcation, and/or activities of growth factors (e.g.
TGFb) implicated in osteophyte development. We suggest that the lack
of perlecan domain I HS chains negates FGF-18 sequestration, altering
signalling effects and in vivo cartilage remodeling. Controlling the
synthesis and/or turnover of chondrocyte perlecan and/or HS substi-
tution may provide a therapeutic target alone or in combination with
FGF-18 in the treatment in OA.
